I am reading the trial table rather than the press release, which is why the numbers differ.
I would like the mechanism, because I want to be able to reason about the cases nobody has written about.
I have tried to reason it out from first principles and got to two contradictory conclusions.
What is actually going on here, physically?
It helps to be literal here: glucose-dependence is the property that makes the class behave the way it does, and most safety questions here resolve back to it.
The SURPASS programme evaluated tirzepatide in type 2 diabetes across several comparators, and the SUSTAIN programme did the same for semaglutide. Those are the diabetes trials; SURMOUNT and STEP are the obesity ones, and quoting across them is the most common citation error in this area.
| Quantity | Value | Derivation |
|---|---|---|
| Control-arm event rate | 8.0 % | From the trial table, not the abstract |
| Hazard ratio | 0.80 | Reported |
| Treated event rate | 6.4 % | 8.0 × 0.80 |
| Absolute risk reduction | 1.6 pp | 8.0 − 6.4 |
| Number needed to treat | 63 | 1 ÷ 0.016 |
| Relative risk reduction | 20 % | 1 − 0.80 |
The last two rows describe the same finding. Only one of them is used in headlines.
Gastric emptying delay contributes to postprandial glucose control and attenuates with continued exposure for the short-acting agents, less so for the long-acting ones.
The caveat is unavoidable here: diabetes management involves other medications whose doses interact with this one, and that is a clinician's job rather than a forum's.
Hypoglycaemia risk is about what else is on board, not about this class in isolation.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsStart from baseline glycaemia. Absolute HbA1c reduction is strongly baseline-dependent, so a trial enrolling at 8.5 per cent and one enrolling at 7.5 per cent will report different reductions from the same drug effect.
Because the insulinotropic effect is glucose-dependent, hypoglycaemia in monotherapy is uncommon. It becomes common when combined with a sulfonylurea or insulin, and that is a dose-adjustment question rather than a class limitation.
The underlying point is that fasting plasma glucose and postprandial excursion respond on different timescales, and a fasting number alone will underestimate what has happened to the postprandial curve.
SURPASS-2 compared tirzepatide directly against semaglutide 1 mg in type 2 diabetes, which is the head-to-head result people usually mean when they claim one is stronger than the other.
Time-in-range tells you more than a quarterly average for an agent that works postprandially.
Answering this needs the background therapy. Added to metformin alone and added to insulin are different questions with different safety profiles.
Weight loss contributes to insulin sensitivity independently, so part of the glycaemic effect in a person losing fifteen per cent of body weight is not directly receptor-mediated.
HbA1c reductions of roughly one and a half to two and a quarter percentage points were reported at the higher doses in these programmes, from baselines around eight per cent, with the larger reductions from the higher baselines.
Trial-average HbA1c reductions conceal a wide individual range, and the average is not a prediction about a person.
The glucose-dependent mechanism explains most of the safety profile, and it is worth understanding once.
edited 6 Dec 2025 by ilaria_bertone — tightened the wording; no substantive change
The honest answer is that the glycaemic evidence here is among the strongest in the field and that the individual response range is wide.
Beta-cell function markers improve during treatment in these trials and revert on withdrawal, which is consistent with functional rather than structural change.
Nothing here is medical advice. Anyone taking insulin or a sulfonylurea has a hypoglycaemia question that needs answering properly.
Baseline HbA1c drives the size of the reduction more than anything else in the protocol.
Answer first: glycaemic efficacy in this class is dose-dependent and consistent, and the trials to quote are the dedicated diabetes programmes rather than the obesity ones.
Time-in-range from continuous monitoring is a more informative endpoint than HbA1c for this class specifically, because it captures the postprandial effect that an average conceals.
Quote SURPASS and SUSTAIN for glycaemia; quote SURMOUNT and STEP for weight. They are different programmes.
edited 18 Feb 2026 by cap_the_luer — reworded for clarity after a comment
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.